-
Product Insights
NewKappa Type Opioid Receptor – Drugs In Development, 2024
The Kappa Type Opioid Receptor pipeline drugs market research report outlays comprehensive information on the Kappa Type Opioid Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Dermatology, Toxicology, and Gastrointestinal which include indications of Pain, Opium (Opioid) Addiction, Pruritus, Uremic (Renal) Pruritus, Acute Opioid Overdosage, Drug Overdose, Irritable Bowel Syndrome, and Diarrhea. It...
-
Product Insights
NewInhibitor of Nuclear Factor Kappa B Kinase Subunit Beta – Drugs In Development, 2024
The Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta pipeline drugs market research report outlays comprehensive information on the Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Genito Urinary System, and Gastrointestinal which include indications of Melanoma, Glioblastoma Multiforme (GBM), Inflammation, Acute Renal Failure (ARF)...
-
Innovation Ranking
Innovation Ranking – Smurfit Kappa Group plc
Smurfit Kappa Group Plc (Smurfit) is a provider of paper packaging solutions. It manufactures, distributes and markets corrugated containers, container boards and other paper-based packaging products. The company’s product offerings include graphic and solid boards, paper bags, protective packaging products, container boards, kraftliners, corrugated and packaging products. It also offers recovered papers, packaging machinery, pulp, testliners, preprinted liners, retail packaging, postal packaging, point of sale displays, seedlings, and bag-in-box. The company also provides services such as packaging design and consultancy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GIM-122 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GIM-122 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GIM-122 in Solid Tumor Drug Details: GIM-122 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anti-RANKL Monoclonal Antibody in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anti-RANKL Monoclonal Antibody in Osteoporosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anti-RANKL Monoclonal Antibody in Osteoporosis Drug Details: The therapeutic candidate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MW-032 in Bone Metastasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MW-032 in Bone Metastasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MW-032 in Bone Metastasis Drug Details: Denosumab biosimilar is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Post Menopausal Osteoporosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Post Menopausal Osteoporosis Drug Details: Denosumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LY-01011 in Giant Cell Tumor Of Bone
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LY-01011 in Giant Cell Tumor Of Bone report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-01011 in Giant Cell Tumor Of Bone Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HSK-21542 in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HSK-21542 in Post-Operative Pain report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HSK-21542 in Post-Operative Pain Drug Details: HSK-21542 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NILK-2301 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NILK-2301 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NILK-2301 in Solid Tumor Drug Details: NI-2301 is under development for...